Evidence map›Paper›PMID 26861145›Full record

ArticleThe international journal of neuropsychopharmacology2016

Emotional Impairment and Persistent Upregulation of mGlu5 Receptor following Morphine Abstinence: Implications of an mGlu5-MOPr Interaction.

Panos Zanos, Polymnia Georgiou, Loreto Rojo Gonzalez, Susanna Hourani, Ying Chen, Ian Kitchen, Brigitte L Kieffer, Raphaelle Winsky-Sommerer, Alexis Bailey

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The international journal of neuropsychopharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Role of α1-GABAJournal of psychopharmacology (Oxford, England) · 2024
    Article
  5. Article
  6. Review
  7. Article
  8. Glutamatergic Systems and Memory Mechanisms Underlying Opioid Addiction.Cold Spring Harbor perspectives in medicine · 2021
    Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 4 countries.

Panos ZanosSchool of Biosciences and Medicine, Faculty of Health and Medical Sciences, University of Surrey, Guildford, Surrey, UK (Dr Zanos, Dr Georgiou, Ms Rojo Gonzalez, Prof. Hourani, Prof. Kitchen, Dr Winsky-Sommerer, and Dr Bailey); Department of Psychiatry, University of Maryland, School of Medicine, Baltimore, MD (Dr Zanos and Dr Georgiou); Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, UK (Dr Chen); Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Université de Strasbourg, Illkirch, France (Prof. Kieffer); Douglas Hospital Research Center, Department of Psychiatry, Faculty of Medicine, McGill University, Montreal, Quebec, Canada (Prof. Kieffer); Institute of Medical and Biomedical Education, St George's University of London, London (Dr Bailey).
Polymnia GeorgiouSchool of Biosciences and Medicine, Faculty of Health and Medical Sciences, University of Surrey, Guildford, Surrey, UK (Dr Zanos, Dr Georgiou, Ms Rojo Gonzalez, Prof. Hourani, Prof. Kitchen, Dr Winsky-Sommerer, and Dr Bailey); Department of Psychiatry, University of Maryland, School of Medicine, Baltimore, MD (Dr Zanos and Dr Georgiou); Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, UK (Dr Chen); Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Université de Strasbourg, Illkirch, France (Prof. Kieffer); Douglas Hospital Research Center, Department of Psychiatry, Faculty of Medicine, McGill University, Montreal, Quebec, Canada (Prof. Kieffer); Institute of Medical and Biomedical Education, St George's University of London, London (Dr Bailey).
Loreto Rojo GonzalezSchool of Biosciences and Medicine, Faculty of Health and Medical Sciences, University of Surrey, Guildford, Surrey, UK (Dr Zanos, Dr Georgiou, Ms Rojo Gonzalez, Prof. Hourani, Prof. Kitchen, Dr Winsky-Sommerer, and Dr Bailey); Department of Psychiatry, University of Maryland, School of Medicine, Baltimore, MD (Dr Zanos and Dr Georgiou); Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, UK (Dr Chen); Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Université de Strasbourg, Illkirch, France (Prof. Kieffer); Douglas Hospital Research Center, Department of Psychiatry, Faculty of Medicine, McGill University, Montreal, Quebec, Canada (Prof. Kieffer); Institute of Medical and Biomedical Education, St George's University of London, London (Dr Bailey).
Susanna HouraniSchool of Biosciences and Medicine, Faculty of Health and Medical Sciences, University of Surrey, Guildford, Surrey, UK (Dr Zanos, Dr Georgiou, Ms Rojo Gonzalez, Prof. Hourani, Prof. Kitchen, Dr Winsky-Sommerer, and Dr Bailey); Department of Psychiatry, University of Maryland, School of Medicine, Baltimore, MD (Dr Zanos and Dr Georgiou); Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, UK (Dr Chen); Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Université de Strasbourg, Illkirch, France (Prof. Kieffer); Douglas Hospital Research Center, Department of Psychiatry, Faculty of Medicine, McGill University, Montreal, Quebec, Canada (Prof. Kieffer); Institute of Medical and Biomedical Education, St George's University of London, London (Dr Bailey).
Ying ChenSchool of Biosciences and Medicine, Faculty of Health and Medical Sciences, University of Surrey, Guildford, Surrey, UK (Dr Zanos, Dr Georgiou, Ms Rojo Gonzalez, Prof. Hourani, Prof. Kitchen, Dr Winsky-Sommerer, and Dr Bailey); Department of Psychiatry, University of Maryland, School of Medicine, Baltimore, MD (Dr Zanos and Dr Georgiou); Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, UK (Dr Chen); Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Université de Strasbourg, Illkirch, France (Prof. Kieffer); Douglas Hospital Research Center, Department of Psychiatry, Faculty of Medicine, McGill University, Montreal, Quebec, Canada (Prof. Kieffer); Institute of Medical and Biomedical Education, St George's University of London, London (Dr Bailey).
Ian KitchenSchool of Biosciences and Medicine, Faculty of Health and Medical Sciences, University of Surrey, Guildford, Surrey, UK (Dr Zanos, Dr Georgiou, Ms Rojo Gonzalez, Prof. Hourani, Prof. Kitchen, Dr Winsky-Sommerer, and Dr Bailey); Department of Psychiatry, University of Maryland, School of Medicine, Baltimore, MD (Dr Zanos and Dr Georgiou); Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, UK (Dr Chen); Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Université de Strasbourg, Illkirch, France (Prof. Kieffer); Douglas Hospital Research Center, Department of Psychiatry, Faculty of Medicine, McGill University, Montreal, Quebec, Canada (Prof. Kieffer); Institute of Medical and Biomedical Education, St George's University of London, London (Dr Bailey).
Brigitte L KiefferSchool of Biosciences and Medicine, Faculty of Health and Medical Sciences, University of Surrey, Guildford, Surrey, UK (Dr Zanos, Dr Georgiou, Ms Rojo Gonzalez, Prof. Hourani, Prof. Kitchen, Dr Winsky-Sommerer, and Dr Bailey); Department of Psychiatry, University of Maryland, School of Medicine, Baltimore, MD (Dr Zanos and Dr Georgiou); Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, UK (Dr Chen); Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Université de Strasbourg, Illkirch, France (Prof. Kieffer); Douglas Hospital Research Center, Department of Psychiatry, Faculty of Medicine, McGill University, Montreal, Quebec, Canada (Prof. Kieffer); Institute of Medical and Biomedical Education, St George's University of London, London (Dr Bailey).
Raphaelle Winsky-SommererSchool of Biosciences and Medicine, Faculty of Health and Medical Sciences, University of Surrey, Guildford, Surrey, UK (Dr Zanos, Dr Georgiou, Ms Rojo Gonzalez, Prof. Hourani, Prof. Kitchen, Dr Winsky-Sommerer, and Dr Bailey); Department of Psychiatry, University of Maryland, School of Medicine, Baltimore, MD (Dr Zanos and Dr Georgiou); Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, UK (Dr Chen); Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Université de Strasbourg, Illkirch, France (Prof. Kieffer); Douglas Hospital Research Center, Department of Psychiatry, Faculty of Medicine, McGill University, Montreal, Quebec, Canada (Prof. Kieffer); Institute of Medical and Biomedical Education, St George's University of London, London (Dr Bailey).
Alexis BaileySchool of Biosciences and Medicine, Faculty of Health and Medical Sciences, University of Surrey, Guildford, Surrey, UK (Dr Zanos, Dr Georgiou, Ms Rojo Gonzalez, Prof. Hourani, Prof. Kitchen, Dr Winsky-Sommerer, and Dr Bailey); Department of Psychiatry, University of Maryland, School of Medicine, Baltimore, MD (Dr Zanos and Dr Georgiou); Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, UK (Dr Chen); Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Université de Strasbourg, Illkirch, France (Prof. Kieffer); Douglas Hospital Research Center, Department of Psychiatry, Faculty of Medicine, McGill University, Montreal, Quebec, Canada (Prof. Kieffer); Institute of Medical and Biomedical Education, St George's University of London, London (Dr Bailey). abailey@sgul.ac.uk.
Douglas Mental Health University Institute · CAInserm · FRMcGill University · CAUniversity of Maryland, Baltimore · USUniversité de Strasbourg · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA difficult problem in treating opioid addicts is the maintenance of a drug-free state because of the negative emotional symptoms associated with withdrawal, which may trigger relapse. Several lines of evidence suggest a role for the metabotropic glutamate receptor 5 in opioid addiction; however, its involvement during opioid withdrawal is not clear.

methodsMice were treated with a 7-day escalating-dose morphine administration paradigm. Following withdrawal, the development of affective behaviors was assessed using the 3-chambered box, open-field, elevated plus-maze and forced-swim tests. Metabotropic glutamate receptor 5 autoradiographic binding was performed in mouse brains undergoing chronic morphine treatment and 7 days withdrawal. Moreover, since there is evidence showing direct effects of opioid drugs on the metabotropic glutamate receptor 5 system, the presence of an metabotropic glutamate receptor 5/μ-opioid receptor interaction was assessed by performing metabotropic glutamate receptor 5 autoradiographic binding in brains of mice lacking the μ-opioid receptor gene.

resultsWithdrawal from chronic morphine administration induced anxiety-like, depressive-like, and impaired sociability behaviors concomitant with a marked upregulation of metabotropic glutamate receptor 5 binding. Administration of the metabotropic glutamate receptor 5 antagonist, 3-((2-Methyl-4-thiazolyl)ethynyl)pyridine, reversed morphine abstinence-induced depressive-like behaviors. A brain region-specific increase in metabotropic glutamate receptor 5 binding was observed in the nucleus accumbens shell, thalamus, hypothalamus, and amygdala of μ-opioid receptor knockout mice compared with controls.

conclusionsThese results suggest an association between metabotropic glutamate receptor 5 alterations and the emergence of opioid withdrawal-related affective behaviors. This study supports metabotropic glutamate receptor 5 system as a target for the development of pharmacotherapies for the treatment of opioid addiction. Moreover, our data show direct effects of μ-opioid receptor system manipulation on metabotropic glutamate receptor 5 binding in the brain.

Indexed as

AnimalsBehavior, AnimalBrainEmotionsMaleMiceMice, KnockoutMorphineReceptor, Metabotropic Glutamate 5Receptors, Opioid, muSubstance Withdrawal SyndromeUp-RegulationMorphineReceptor, Metabotropic Glutamate 5Receptors, Opioid, mumGlu5RMorphineopioidswithdrawalμ-opioid receptor

Identifiers

PMID26861145
PMCPMC4966274
OpenAlexW2259890699

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.